| Molecular therapies and precision medicine for hepatocellular carcinoma JM Llovet, R Montal, D Sia, RS Finn Nature reviews Clinical oncology 15 (10), 599-616, 2018 | 1732 | 2018 |
| Liver cancer cell of origin, molecular class, and effects on patient prognosis D Sia, A Villanueva, SL Friedman, JM Llovet Gastroenterology 152 (4), 745-761, 2017 | 1190 | 2017 |
| Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features D Sia, Y Jiao, I Martinez-Quetglas, O Kuchuk, C Villacorta-Martin, ... Gastroenterology 153 (3), 812-826, 2017 | 857 | 2017 |
| β-catenin activation promotes immune escape and resistance to anti–PD-1 therapy in hepatocellular carcinoma M Ruiz de Galarreta, E Bresnahan, P Molina-Sánchez, KE Lindblad, ... Cancer discovery 9 (8), 1124-1141, 2019 | 724 | 2019 |
| Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes D Sia, Y Hoshida, A Villanueva, S Roayaie, J Ferrer, B Tabak, J Peix, ... Gastroenterology 144 (4), 829-840, 2013 | 601 | 2013 |
| Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer SK Saha, CA Parachoniak, KS Ghanta, J Fitamant, KN Ross, MS Najem, ... Nature 513 (7516), 110-114, 2014 | 524 | 2014 |
| Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis S Moran, A Martínez-Cardús, S Sayols, E Musulén, C Balañá, ... The Lancet Oncology 17 (10), 1386-1395, 2016 | 482 | 2016 |
| Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma A Villanueva, Y Hoshida, C Battiston, V Tovar, D Sia, C Alsinet, ... Gastroenterology 140 (5), 1501-1512. e2, 2011 | 474 | 2011 |
| Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma D Sia, B Losic, A Moeini, L Cabellos, K Hao, K Revill, D Bonal, ... Nature communications 6 (1), 6087, 2015 | 323 | 2015 |
| Intratumoral heterogeneity and clonal evolution in liver cancer B Losic, AJ Craig, C Villacorta-Martin, SN Martins-Filho, N Akers, X Chen, ... Nature communications 11 (1), 291, 2020 | 313 | 2020 |
| Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations S Affo, A Nair, F Brundu, A Ravichandra, S Bhattacharjee, M Matsuda, ... Cancer cell 39 (6), 866-882. e11, 2021 | 308 | 2021 |
| Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma J Bollard, V Miguela, MR De Galarreta, A Venkatesh, CB Bian, ... Gut 66 (7), 1286-1296, 2017 | 281 | 2017 |
| YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression J Fitamant, F Kottakis, S Benhamouche, HS Tian, N Chuvin, ... Cell reports 10 (10), 1692-1707, 2015 | 274 | 2015 |
| Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial R Pinyol, R Montal, L Bassaganyas, D Sia, T Takayama, GY Chau, ... Gut 68 (6), 1065-1075, 2019 | 272 | 2019 |
| Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies D Sia, V Tovar, A Moeini, JM Llovet Oncogene 32 (41), 4861-4870, 2013 | 271 | 2013 |
| Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma A Moeini, D Sia, N Bardeesy, V Mazzaferro, JM Llovet Clinical Cancer Research 22 (2), 291-300, 2016 | 261 | 2016 |
| Cancer gene discovery in hepatocellular carcinoma L Zender, A Villanueva, V Tovar, D Sia, DY Chiang, JM Llovet Journal of hepatology 52 (6), 921-929, 2010 | 247 | 2010 |
| Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma R Montal, D Sia, C Montironi, WQ Leow, R Esteban-Fabró, R Pinyol, ... Journal of hepatology 73 (2), 315-327, 2020 | 241 | 2020 |
| Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC R Pinyol, D Sia, JM Llovet Clinical Cancer Research 25 (7), 2021-2023, 2019 | 204 | 2019 |
| Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma V Tovar, H Cornella, A Moeini, S Vidal, Y Hoshida, D Sia, J Peix, ... Gut 66 (3), 530-540, 2017 | 203 | 2017 |
